Nanomedicine · 2010 · 29 citations · 24 references
PharmacyOncologyPharmaceuticsDrug DeliveryMetastasisNanoparticle Drug DeliveryCancer NanomedicineMagnetic NanomaterialsNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNanoparticle Delivery SystemsCell Surface Recognition ReceptorsControl Group DesignMagnetic Drug Delivery SystemsMagnetic Nanoparticle Drug CarriersMagnetic Nanoparticle Drug DeliveryMagnetic NanoparticlesNanoparticlesTumor Progression Dynamics
AIMS: To slow tumor progression by reducing migratory tumor cell burden using magnetic nanoparticles (MNPs) functionalized with ligands selective for malignant cell surface receptors. MATERIALS & METHODS: Three groups of female C57BL/6 mice (control group I, control group II and experimental group) were intraperitoneally injected with a murine ovarian cancer cell line (ID8[VEGF160(+)/eGFP(+)]). Control group I received no intervention. MNPs were functionalized with ephrin-A1 mimetic peptides selective for the EphA2 receptor that is highly expressed by several cancers. Peritoneal fluids were removed by paracentesis from the experimental group and mixed with the functionalized MNPs. Magnetic filtration was used to remove particle/malignant cell conjugates and filtered peritoneal fluids were re-introduced intraperitoneally. Control group II received the same treatment as the experimental group without MNPs. RESULTS: Experimental group tumor progression was 10.77-times slower than that of control group I. CONCLUSION: Reduction of malignant cell titer significantly prolonged time to end point in a metastatic ovarian cancer model.
24
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2008 · 10.2K citations · Full text
G. David Roodman · New England Journal of Medicine · 2004 · 2.7K citations
Medicine, Oncology, Bone Metabolism +12
How to Detect and Handle Outliers
Teri A. Crosby, Boris Iglewicz, David C. Hoaglin · Technometrics · 1994 · 764 citations